| Autor: |
Alves RC; Department of Drugs and Medicines, School of Pharmaceutical Sciences, São Paulo State University (UNESP), Rodovia Araraquara Jau, Km 01-s/n-Campos Ville, Araraquara 14800-903, Brazil., Perosa Fernandes R; Department of Chemistry, Federal University of Mato Grosso (UFMT), Cuiabá 78060-900, Brazil., Lira de Farias R; Departament of Chemical, Pontifícia Universidade Católica do Rio de Janeiro, Rio de Janeiro 22451-900, Brazil., da Silva PB; Department of Genetics and Morphology, Institute of Biological Sciences, University of Brasilia (UnB), Campus Universitario Darcy Ribeiro-Asa Norte, Brasilia 70910-900, Brazil., Santos Faria R; Department of Genetics and Morphology, Institute of Biological Sciences, University of Brasilia (UnB), Campus Universitario Darcy Ribeiro-Asa Norte, Brasilia 70910-900, Brazil., Quijia CR; Department of Drugs and Medicines, School of Pharmaceutical Sciences, São Paulo State University (UNESP), Rodovia Araraquara Jau, Km 01-s/n-Campos Ville, Araraquara 14800-903, Brazil., Galvão Frem RC; Chemistry Institute, São Paulo State University (UNESP), Campus Araraquara, Araraquara 14800-060, Brazil., Azevedo RB; Department of Genetics and Morphology, Institute of Biological Sciences, University of Brasilia (UnB), Campus Universitario Darcy Ribeiro-Asa Norte, Brasilia 70910-900, Brazil., Chorilli M; Department of Drugs and Medicines, School of Pharmaceutical Sciences, São Paulo State University (UNESP), Rodovia Araraquara Jau, Km 01-s/n-Campos Ville, Araraquara 14800-903, Brazil. |
| Abstrakt: |
Breast cancer is the most frequent cause of cancer death in women, representing the fifth leading cause of cancer death overall. Therefore, the growing search for the development of new treatments for breast cancer has been developed lately as well as drug delivery systems such as biocompatible metal-organic Frameworks (bio-MOFs). These may be promising and attractive for drug incorporation and release. The present study aims to develop a drug carrier system RCA (bioMOF-100 submitted to the activation process) containing incorporated curcumin (CCM), whose material surface is coated with folic acid molecules (FA) to promote the targeting of drug carrier systems to the tumor region. They were synthesized and characterized using several characterization techniques. The materials were submitted to drug encapsulation tests, whose encapsulation efficiency was 32.80% for CCM@RCA-1D. Using the 1 H nuclear magnetic resonance (NMR) spectroscopy technique, it was possible to verify the appearance of signals referring to folic acid, suggesting success in the functionalization of these matrices. In vitro tests such as cell viability and type of cell death were evaluated in both series of compounds (CCM@RCA-1D, CCM@RCA-1D/FA) in breast tumor lines. The results revealed low toxicity of the materials and cell death by late apoptosis. Thus, these results indicate that the matrices studied can be promising carriers in the treatment of breast cancer. |
